Pharmakologische befunde mit amisulprid

Psychopharmakotherapie

Volumn 6, Issue SUPPL. 9, 1999, Pages 5-8

  Sanger, D J ^b   Perrault, Gh ^b   Schoemaker, H ^b   Scatton, B ^a  

^a SANOFI   (France)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMISULPRIDE; CLOZAPINE; DOPAMINE 3 RECEPTOR BLOCKING AGENT; DOPAMINE RECEPTOR; HALOPERIDOL; REMOXIPRIDE; RISPERIDONE;

DOPAMINERGIC SYSTEM; DRUG EFFECT; DRUG MECHANISM; DRUG RECEPTOR BINDING; EXTRAPYRAMIDAL SYMPTOM; HUMAN; INTRAPERITONEAL DRUG ADMINISTRATION; PSYCHOPHARMACOLOGY; PSYCHOPHARMACOTHERAPY; SHORT SURVEY;

EID: 0033052869     PISSN: 09446877     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Andreasen NC. Improvement of negative symptoms: Concepts, definition and assessment. Int Clin Psychopharmacol 1998;12(Suppl 2): S7-S10.
2. Bischoff S. Limbic selective neuroleptics. Clin Neuropharmacol 1992;15(Suppl 1 Pt A):265A-266A.
3. Boyer P, Lecrubier Y, Puech AJ, Dewailly J, et al. Treatment of negative symptoms in schizophrenia with amisulpride. Br J Psychiat 1995; 166:68-72.
4. Caley CF, Weber SS. Sulpiride: an antipsychotic with selective dopaminergic antagonist properties. Ann Pharmacother 1995;29:152-60.
5. Creese I, Burt DR, Snyder S. Dopamine receptor binding predicts clinical and pharmacological properties of antischizophrenic drugs. Science 1976;192:481-3.
6. Di Giovanni G, Di Mascio M, Di Matteo V, Esposito E. Effects of acute and repeated administration of amisulpride, a dopamine D2/D3 receptor antagonist, on the electrical activity of midbrain dopaminergic neurons. J Pharmacol Exp Ther 1998. In press.
7. Freeman HL. Amisulpride compared with standard neuroleptics in acute excerbations of schizophrenia: Three efficacy studies. Int Clin Psychopharmacol 1997;12(Suppl 2):S11-S17.
8. Gurevic EV, Bordelon Y, Shapiro RM, Arnold SE, et al. Mesolimbic dopamine D-3 receptors and use of antipsychotics in patients with schizophrenia - A postmortem study. Arch Gen Psychiatry 1997;54:225-32.
9. Guyon A, Assouly-Besse F, Biala G, Puech AJ, et al. Potentiation by low doses of selected neuroleptics of food-induced conditioned place preference in rats. Psychopharmacology 1993; 110:460-6.
10. Joyce JN, Meador-Woodruff JH. Linking the family of D-2 receptors to neuronal circuits in human brain: Insights into schizophrenia. Neuropsychopharmacology 1997;16:375-84.
11. Lidow MS, Williams GV, Goldman-Rakic PS. The cerebral cortex: a case for a common site of action of antipsychotics. Trends Pharmacol Sci 1998;19:136-40.
12. Millan MJ, Peglion JL, Vian J, Rivet JM, et al. Functional correlates of dopamine D3 receptor activation in the rat in vivo and their modulation by the selective antagonist, (+)-S 14297: I. Activation of postsynaptic D3 receptors mediates hypothermia, whereas blockade of D2 receptors elicits prolactin secretion and catalepsy. J Pharmacol Exp Ther 1995;275:885-98.
13. Perrault Gh, Depoortere R, Morel E, Sanger DJ, et al. Psychopharmalogical profile of amisulpride: an antipsychotic drug with presynaptic D2/D3 dopamine receptor antagonist activity and limbic selectivity. J Pharmacol Exp Ther 1997;280:73-82.
14. Rein W, Turjanski S. Clinical update on amisulpride in deficit schizophrenia. Int Clin Psychopharmacol 1997;12(Suppl 2):S19-S27.
15. Sanger DJ, Depoortere R, Perrault Gh. Discriminative stimulus effects of apomorphine and 7-OH-DPAT: a potential role for dopamine D3 receptors. Psychopharmacology 1997;130: 387-95.
16. Scatton B, Bischoff S, Dedek J, Korf J. Regional effects of neuroleptics on dopamine metabolism and dopamine-sensitive adenylate cyclase activity. Eur J Pharmacol 1977;44: 287-92.
17. Scatton B, Claustre Y, Cudennec A, Oblin A, et al. Amisulpride: from animal pharmacology to therapeutic action. Int Clin Psychopharmacol 1997;12(Suppl 2):S29-S36.
18. Schoemaker H, Claustre Y, Fage D, Rouquier L, et al. Neurochemical characteristics of amisulpride, an atypical dopamine D2/D3 receptor antagonist with both presynaptic and limbic selectivity. J Pharmacol Exp Ther 1997; 280:83-97.
19. Sokoloff P, Giros B, Martres MP, Bouthenet ML, et al. Molecular cloning and characterization of a novel dopamine receptor (D3) as a target for neuroleptics. Nature 1990;347:146-51.
20. Suaud-Chagny MF, Ponec J, Gonon F. Presynaptic autoinhibition of the electrically evoked dopamine release studied in the rat olfactory tubercle by in vivo electrochemistry. Neuroscience 1991;45:641-52.
21. Willner P. The dopamine hypothesis of schizophrenia: current status, future prospects. Int Clin Psychopharmacol 1997;12:297-308.
22. Cudennec JA, Fage D, Benavides J, Scatton B. Effects of amisulpride, an atypical antipsychotic, which blocks preferentially presynaptic dopamine autoreceptors, on integrated functional cerebral activitiy in the rat. Brain Res 1997;768:257-65.